SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Fixed-dose combination antibiotics: the search for evidence using the example of ampicillin-cloxacillin.

Sayer, B; Bortone, B; Sharland, M; Hsia, Y (2021) Fixed-dose combination antibiotics: the search for evidence using the example of ampicillin-cloxacillin. Br J Clin Pharmacol, 87 (7). pp. 2996-2999. ISSN 1365-2125 https://doi.org/10.1111/bcp.14711
SGUL Authors: Hsia, Yingfen Sharland, Michael Roy

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (540kB) | Preview
[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (32kB)

Abstract

High consumption of irrational fixed-dose combination (FDC) antibiotics may pose a threat of antimicrobial resistance. In India, ampicillin-cloxacillin was the second highest sold FDC antibiotic behind amoxicillin and clavulanic acid. There however remain questions about its efficacy and safety and a lack of regulatory approval. We undertook a literature review for ampicillin-cloxacillin to identify available data on the safety and efficacy of its used as FDC. We identified 1071 studies for screening and 81 studies were considered for inclusion. Only 12 studies in English language were accessible full texts for final review. None of the studies identified provided strong evidence that ampicillin-cloxacillin differed in safety or efficacy to other treatments used, and in particular to the component antibiotics used alone. To fully assess the efficacy and safety of ampicillin-cloxacillin and other FDCs, a standardised search format would be required. This should include broad international collaboration, including contacting the relevant regulatory authorities to facilitate a more evidence based approach to their use.

Item Type: Article
Additional Information: © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Keywords: antibiotics, antimicrobial resistance, fixed-dose combination, literature review, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Br J Clin Pharmacol
ISSN: 1365-2125
Language: eng
Dates:
DateEvent
28 June 2021Published
11 January 2021Published Online
29 November 2020Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 33368470
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/112679
Publisher's version: https://doi.org/10.1111/bcp.14711

Actions (login required)

Edit Item Edit Item